ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2025
Clinical efficacy, safety and prognostic factors of photodynamic therapy for human papillomavirus infection with vaginal squamous intraepithelial lesion.
Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe management of vaginal intraepithelial neoplasia (VaIN) is complicated by its high recurrence rate and the significant drawbacks of conventional therapies, which range from poor adherence to drug regimens to the invasiveness of surgical procedures. 5-aminolevulinic acid photodynamic therapy (ALA-PDT) represents a promising, non-invasive therapeutic modality for this condition.
objectiveThis study aimed to investigate the clinical efficacy, safety and prognosis of ALA-PDT in the treatment of human papillomavirus (HPV) infection complicated with VaIN.
methodsBetween 1 January 2022 and 31 July 2024, a total of 156 patients diagnosed with VaIN were retrospectively identified through convenience sampling at the Obstetrics and Gynecology Clinic of the First Affiliated Hospital of Bengbu Medical University. Clinical treatment and follow-up data were collected for retrospective analysis.
resultsNo significant differences were observed in cervical disease, lesion location, body mass index, HPV type or disease classification across different age groups (p > 0.05). Similarly, there were no statistically significant differences in the proportions of ThinPrep cytologic test negativity, HPV negativity, pathological recovery, patient satisfaction or adverse reactions among different age groups, HPV type groups or disease groups at 3, 6 and 12 months following the final treatment (p > 0.05).
conclusionThe results demonstrate that ALA-PDT is a safe and effective treatment for HPV infection combined with VaIN, with minimal side effects. Its therapeutic efficacy is not influenced by disease type, patient age group or HPV infection subtype.
Indexed as
Identifiers
41212398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.